Zhang Wei-wei, Liu Ke-jun, Hu Guo-lin, Liang Wei-jiang
Department of Medical Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Department of Medical Oncology, The Sixth People's Hospital of Chengdu, Chengdu, 610051, China.
Tumour Biol. 2015 Nov;36(11):8831-7. doi: 10.1007/s13277-015-3533-9. Epub 2015 Jun 11.
The aim of the present study was to determine the most meaningful preoperative prognostic factor of cancer-related death in ovarian cancer patients by comparing potentially prognostic systemic inflammatory response (SIR) markers. The levels of fibrinogen, albumin, C-reactive protein (CRP), and serum cancer antigen-125 (CA-125) and the neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) were evaluated in 190 ovarian cancer patients to identify predictors of overall survival (OS) and progression-free survival (PFS) using univariate and multivariate analyses. Patients with a PLR >203 had a shorter PFS and OS than the patients in PLR ≤203 group (11 vs. 24 months and 28 vs. 64 months). Univariate analyses revealed that tumor stage, postoperative residual tumor mass, ascites, and the levels of all SIR markers were associated with PFS and OS. Multivariate analysis revealed that PLR was independently associated with PFS (hazard ratio [HR] 1.852, 95% confidence interval [CI] 1.271-2.697, P = 0.001) and OS (HR 2.158, 95%CI 1.468-3.171, P < 0.001), as well as tumor stage and postoperative residual tumor mass. In contrast, fibrinogen remained significant only for PFS (HR 1.724, 95%CI 1.197-2.482, P = 0.003). Patients with a PLR >203 were more prone to have advanced tumor stage (P = 0.002), postoperative residual tumor mass >2 cm (P = 0.032), malignant ascites (P < 0.001), and all the other elevated SIR markers (P < 0.001). Preoperative PLR is superior to other SIR markers (CA-125, NLR, fibrinogen, CRP, and albumin) as a predictor of survival in ovarian cancer patients.
本研究的目的是通过比较潜在的预后性全身炎症反应(SIR)标志物,确定卵巢癌患者癌症相关死亡最有意义的术前预后因素。对190例卵巢癌患者的纤维蛋白原、白蛋白、C反应蛋白(CRP)、血清癌抗原125(CA-125)水平以及中性粒细胞/淋巴细胞比值(NLR)和血小板/淋巴细胞比值(PLR)进行评估,采用单因素和多因素分析确定总生存期(OS)和无进展生存期(PFS)的预测因素。PLR>203的患者较PLR≤203组患者的PFS和OS更短(分别为11个月对24个月和28个月对64个月)。单因素分析显示,肿瘤分期、术后残留肿瘤大小、腹水以及所有SIR标志物水平均与PFS和OS相关。多因素分析显示,PLR与PFS(风险比[HR]1.852,95%置信区间[CI]1.271-2.697,P = 0.001)和OS(HR 2.158,95%CI 1.468-3.171,P < 0.001)独立相关,同时还与肿瘤分期和术后残留肿瘤大小相关。相比之下,纤维蛋白原仅对PFS仍具有显著意义(HR 1.724,95%CI 1.197-2.482,P = 0.003)。PLR>203的患者更易出现肿瘤分期较晚(P = 0.002)、术后残留肿瘤大小>2 cm(P = 0.032)、恶性腹水(P < 0.001)以及所有其他升高的SIR标志物(P < 0.001)。术前PLR作为卵巢癌患者生存的预测指标优于其他SIR标志物(CA-125、NLR、纤维蛋白原、CRP和白蛋白)。